The aim of CPV 2.0 study is to evaluate a process of digital prevalidation of outpatients chemotherapy thanks to a numeric application. This digital tool is based on the combination of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) to a decisional algorithm.

After cycle 1, chemotherapy digital prevalidation will be done with the help of a nurse for two consecutive cycles (cycles 2 and 3). Patients will then have to use to application by themselves for the two following cycles (cycles 4 and 5)

Inclusion Criteria:

• Age <80 (if age>70 years, a G8 score>14 is required)
• ECOG<3
• Pathology (solid tumor, in neoadjuvant, adjuvant or metastatic setting)
• Patient receiving an IV cytotoxic chemotherapy in a day treatlent unit for at least 5 cycles, with at least an injection at day 1, day 8 and day 15
• Familiar with digital tools

Exclusion Criteria:

• Emergency
• patient feeling unease with the use of a smartphone